Elicio Therapeutics, Inc. (ELTX)
NASDAQ: ELTX · Real-Time Price · USD
10.80
-0.56 (-4.93%)
At close: Apr 28, 2026, 4:00 PM EDT
10.80
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:10 PM EDT
Elicio Therapeutics Employees
Elicio Therapeutics had 33 employees as of December 31, 2025. The number of employees increased by 1 or 3.13% compared to the previous year.
Employees
33
Change (1Y)
1
Growth (1Y)
3.13%
Revenue / Employee
n/a
Profits / Employee
-$1,199,121
Market Cap
198.68M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Voyager Therapeutics | 141 |
| Heron Therapeutics | 128 |
| MediWound | 121 |
| Nkarta | 108 |
| Caribou Biosciences | 97 |
| OmniAb | 89 |
| Keros Therapeutics | 78 |
| ALX Oncology Holdings | 43 |
ELTX News
- 12 days ago - Elicio Therapeutics Reports Inducement Grants - GlobeNewsWire
- 6 weeks ago - Elicio Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 7 weeks ago - Elicio Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference - Transcripts
- 2 months ago - Elicio Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference - GlobeNewsWire
- 4 months ago - Elicio Therapeutics Reports Antigen Spreading to Patient-Specific Neoantigens Beyond mKRAS in Ongoing Phase 2 AMPLIFY-7P Trial - GlobeNewsWire
- 5 months ago - Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer - GlobeNewsWire
- 5 months ago - Elicio Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 6 months ago - Elicio Therapeutics Reports Robust, Cytolytic mKRAS-Specific T Cell Responses Across Diverse Patient HLA in Ongoing Phase 2 AMPLIFY-7P Trial of ELI-002 7P and New ELI-004 Preclinical Data at SITC - GlobeNewsWire